BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
Global measles cases drop 71% in 24 years as vaccination coverage improves, WHO says - 2Hoist Your Style: Famous Hairdos for Ladies
- 3Find Successful Magnificence Items for Sparkling Skin
- 4'Women on the floor, riddled with bullets': Ex-hostage Rom Braslavski recounts 'horrors' of Oct. 7
- 5Famous Places to get-away for Americans
- Cuba says 33 have died of mosquito-borne illnesses as epidemic rages
- Overhaul Your Rest: Tips for a Serene Evening
- Safeguarding Your Senior Protection Against Extortion and Tricks.
- Hilary Duff releases 'Mature,' her 1st song in 10 years
- Los Angeles County sees significant uptick in norovirus cases, officials say
- What you need to know about Trump accounts as Michael and Susan Dell donate $6 billion to the new early childhood investment program
- The Way to Business: Startup Illustrations Learned
- Why is Jerome Powell being investigated? Making sense of the DOJ's probe into the Federal Reserve chair.
- Kidneys from Black donors are more likely to be thrown away − a bioethicist explains why
